Please ensure Javascript is enabled for purposes of website accessibility

Why Ocugen Is Rallying Today

By Zhiyuan Sun – Aug 6, 2021 at 4:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Finally, a bit of good news for this oversold biotech.

Shares of coronavirus vaccine developer Ocugen (OCGN -0.68%) are up 6.74% to $8.00 apiece as of 2:30 p.m. EDT. The company provided business updates in its second-quarter earnings release earlier in the day. It has completed the submission of its India-based partner Bharat Biotech's coronavirus vaccine COVAXIN to regulatory authorities in Canada. The vaccine demonstrated 78% efficacy against overall COVID-19. Ocugen does not have any biologics of its own on the market. It holds commercialization rights for COVAXIN in the U.S. and Canada, and is eligible for 45% of profits from commercialization in the two countries.

Young person proudly pointing at their upper arm where a vaccine shot was given.

Image source: Getty Images.

So what 

Ocugen has been trying to sell 100 million doses of COVAXIN in the U.S. since February. However, in June, the U.S. Food and Drug Administration (FDA) recommended Ocugen file for approval in the form of a Biologic License Application (BLA) instead of an Emergency Use Authorization (EUA). The company also anticipates the need to run another phase 3 study to support the vaccine's approval.

Now what

The lack of a timely launch in the U.S. and of rights to ownership of the vaccine itself means Ocugen only has a market cap of $1.48 billion -- relatively tiny compared to the market cap of competitors like Novavax (NVAX -5.76%) and Moderna (MRNA -1.51%). However, investors are hoping that the vaccine could attain success in Canada, not necessarily for use in domestic vaccination campaigns. The Canadian Government bought 100 million doses of coronavirus vaccines and shared them with developing nations back in June. So there's speculation that COVAXIN could receive orders via the government's equitable distribution program. Still, with no product revenue, it's best to be careful about investing in the speculative biotech.

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$1.46 (-0.68%) $0.01
Novavax Stock Quote
Novavax
NVAX
$15.86 (-5.76%) $0.97
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$170.54 (-1.51%) $-2.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.